Chengdu Olymvax Biopharmaceuticals Inc.   Report issue

For profit Phase 1 Phase 3
Founded: Chengdu China (2009)
Status: No NME R&D (2009)

Organization Overview

First Clinical Trial
2013
NCT02692859
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Chengdu Olymvax Biopharmaceuticals Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Haemophilus Infections (Phase 3)

Influenza, Human (Phase 3)

Staphylococcal Infections (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 4